PRESSEPORTAL Presseportal Logo

mehr Themen

Folgen
Keine Story von LAB International Inc mehr verpassen.
Warum muss ich meine Email-Adresse eingeben?

LAB International Inc

Filtern
  • 10.02.2005 – 14:18

    LAB International Acquires Scantox

    Laval, Canada (ots/PRNewswire) - - Danish Contract Research Organization Will Help Double LAB Research's Revenues LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company with a focus on inhalation delivery, today announced it has acquired all shares of Scantox, Biologisk Laboratorium A/S (Denmark), the leading Scandinavian, non- clinical contract research organization, for a total cash consideration of 28 million ...

    mehr
  • 09.12.2004 – 15:58

    LAB International Shares Trading on the Frankfurt Stock Exchange

    Laval, Quebec (ots/PRNewswire) - LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company focused on the inhalation market, today announced that its shares are available for trading on the Regulated Unofficial Market (Freiverkehr) of the Frankfurt Stock Exchange and on XETRA(R), the Deutsche Borse AG electronic trading system. The inclusion of LAB's securities in the ...

    mehr
  • 06.12.2004 – 18:16

    LAB International to Initiate Phase II Trial for GHRH

    Laval, Canada (ots/PRNewswire) - - Malnutrition in Patients With Late Pre-end-stage Chronic Renal Failure Selected as Clinical Indication for Trial LAB International Inc. (TSX: LAB), an integrated drug development company focused on the inhalation market, today announced that, after completion of a successful dose-response trial, it has selected the first clinical indication for which it intends to evaluate ...

    mehr